Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge

Summary

After prophylactic vaccination with CR8020, a monoclonal antibody, subjects will be challenged with the H3N2 virus. The protective efficacy, safety, tolerability, pharmacokinetics, and potential immunogenicity will be assessed.

Timeline

Start

2013-10-02

Primary completion

2014-01-22

Completion

2014-01-22

Drugs

Indications